Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors by Chang-Lin, Joan-En et al.
© 2011 Chang-Lin et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2011:5 1119–1120
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1119
LeTTer
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/0.2147/OPTH.S23635
Aqueous humor penetration of topical 
bimatoprost 0.01% and bimatoprost 0.03%  
in rabbits: response to authors
Joan-en Chang-Lin  
Amy L Batoosingh 
David A Hollander  
rhett M Schiffman  
Diane D-S Tang-Liu
Allergan, Inc, Irvine, CA, USA
Correspondence: Joan-en Chang-Lin 
Clinical Pharmacology 
Allergan, Inc, 2525 Dupont Drive, T1–1L, 
Irvine, CA 92612, USA 
Tel +1 714 246 4680 
Fax +1 714 796 3138 
email lin_joan-en@allergan.com
We read with great interest the recent article by Ogundele and Jasek,1 in which the 
authors concluded that bimatoprost ophthalmic solution 0.01% (Lumigan®; Allergan, 
Inc, Irvine, CA) produced lower bimatoprost acid concentration than bimatoprost 
ophthalmic solution 0.03% (Lumigan; Allergan, Inc) in the aqueous humor of rabbits. 
This conclusion was made based on two treatment time points (30 and 90 minutes) 
with a small sample size (n = 4) at each time point and with large variability.
In comparing pharmacokinetic profiles of two formulations, it is a general prac-
tice that the study design would support assessment of the speed of onset (ie, time to 
maximum exposure [Tmax]), and the extent of absorption (ie, maximum concentration 
and area under the concentration-time curve). Therefore, a more complete temporal 
profile would be necessary. An erroneous conclusion could be drawn based on two 
seemingly arbitrary time points. For example, it is unclear whether these two time 
points reside in the ascending or descending portion of the temporal profile or if they 
reside one in each portion and the Tmax is missing.
Based on two data points, Ogundele and Jasek1 hypothesized that bimatoprost 
0.01% might have compromised the intraocular pressure (IOP)-lowering effect. Not 
only is there no reported correlation of animal pharmacokinetic and/or metabolism 
results to clinical efficacy, this hypothesis directly contradicts existing evidence.   
A multicenter, 12-month, randomized, controlled trial demonstrated equivalent efficacy 
of bimatoprost 0.01% and bimatoprost 0.03% based on predetermined IOP criteria 
(limits of the 95% confidence interval of the between-group difference in mean IOP 
within ±1.5 mmHg at all time points and within ±1 mmHg at most time points).2
In addition, Ogundele and Jasek1 speculated that bimatoprost 0.01% might have 
increased the risk of ocular toxicity, based on prior publications of in vitro and animal 
studies that may not be relevant to patients, case series, or open-label clinical studies. 
This evidence is considered lower level compared with randomized, controlled trials. 
Katz et al2 conducted a randomized, controlled trial and reported bimatoprost 0.01% had 
(a) significantly lower overall incidence of treatment-related adverse events (P , 0.03); 
(b) significantly reduced conjunctival hyperemia (P , 0.044), skin pigmentation 
(P , 0.02), and eye pruritus (P , 0.035); and (c) significantly lower discontinuation 
rates than bimatoprost 0.03% (P = 0.043). Based on clinical trial evidence, the claims of 
ocular toxicity are unfounded for at least 12 months of administration as monotherapy.2 
In addition, a recent clinical study comparing ocular surface tolerability of topical 
prostaglandin analogs demonstrated no statistical differences following 3 months of Clinical Ophthalmology
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treatment in either corneal staining or conjunctival hyperemia 
between latanoprost, which has 200 ppm benzalkonium 
chloride (BAK), similar to bimatoprost 0.01%, and travoprost 
ophthalmic solution 0.004% (Travatan Z®; Alcon Laborato-
ries, Inc, Fort Worth, TX) (BAK free, preserved with sofZia® 
[Alcon Laboratories, Inc]).3
Bimatoprost 0.01%, which offers improved ocular 
tolerability while maintaining the established efficacy of 
bimatoprost 0.03%, recently gained approval by the European 
Medicines Evaluation Agency (2009) and the US Food and 
Drug Administration (2010) as first-line therapy in patients 
with open-angle glaucoma or ocular hypertension. Any oph-
thalmologist or patient concerns raised by the incomplete and 
potentially misleading conclusion published by Ogundele 
and Jasek1 can be addressed with a carefully constructed 
pharmacokinetic study with a complete time-concentration 
profile. We are currently preparing a manuscript that reports 
the findings of such a study design.
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